Doctors Without Borders Seeks To Undo Gilead Hep C Patent

Law360 (December 5, 2018, 7:51 PM EST) -- Doctors Without Borders and five organizations have appealed the European Patent Office's decision upholding Gilead Sciences Inc.'s patent for the hepatitis C drug sofosbuvir, the international nonprofit announced on Wednesday.

Doctors Without Borders, also known as Médecins Sans Frontières, along with French organizations Médecins du Monde and AIDES, Access to Medicines Ireland, Greece-based Praksis and Spain-based Salud por Derecho, have lodged an appeal over the EPO's September decision to maintain Gilead's patent in amended form, which has purportedly allowed the company to continue charging "excessive prices" for the drug.

The appeal states that the patent does not "meet the requirements to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!